OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press59210.17650/1818-8346-2022-17-4-88-93RARE AND COMPLEX CLINICAL SITUATIONSРЕДКИЕ И СЛОЖНЫЕ КЛИНИЧЕСКИЕ СИТУАЦИИPriapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case reportПриапизм как первый симптом хронического миелолейкоза: обзор литературы и описание собственного клинического наблюденияhttps://orcid.org/0000-0003-4999-5195PavlovaT. Yu.ПавловаТ. Ю.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

md.pavlovaty@mail.ruhttps://orcid.org/0000-0002-1469-2365ValievT. T.ВалиевТ. Т.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России0711202217488930611202206112022https://oncohematology.abvpress.ru/ongm/article/view/592

Chronic myeloid leukemia is a ph-positive myeloproliferative disease, which is usually manifested by hyperleukocytosis and massive splenomegaly. Chronic myeloid leukemia is rare in childhood and adolescence, it accounts for 2 to 3 % of all leukemias cases. priapism is a rare manifestation of chronic myeloid leukemia and is an urgent urological condition that requires timely treatment to prevent long-term complications, in particular, erectile dysfunction.This review presents the literature information about priapism as the first sign of chronic myeloid leukemia, as well as the first description in the Russian literature of a clinical case of priapism in a 9-year-old patient with chronic myeloid leukemia.

Хронический миелолейкоз – ph-позитивное миелопролиферативное заболевание, которое обычно проявляется гиперлейкоцитозом и массивной спленомегалией. хронический миелолейкоз редко встречается в детском и подростковом возрасте, на его долю приходится от 2 до 3 % случаев всех лейкозов. приапизм считается редким проявлением хронического миелоидного лейкоза и представляет собой неотложную урологическую патологию, требующую своевременного лечения для предотвращения долгосрочных осложнений, в частности эректильной дисфункции.В настоящем обзоре представлены данные литературы о приапизме как первом признаке хронического миелолейкоза, а также первое в отечественной литературе описание клинического случая приапизма у пациента 9 лет с хроническим миелолейкозом.

chronic myeloid leukemiachildrenmalignant priapismtyrosine kinase inhibitorхронический миелолейкоздетизлокачественный приапизмингибитор тирозинкиназHoribe K., Saito A.M., Takimoto T. et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006–2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 2013;98(1):74–88. DOI: 10.1007/s12185­013­1364­2Millot F., Traore P., Guilhot J. et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 2005;116(1):140–3. DOI: 10.1542/peds.2004­2473Savage D.G., Szydlo R.M., Goldman J.M. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16­year period. Br J Haematol 1997;96(1):111–6. DOI: 10.1046/j.1365­2141.1997.d01­1982.xRowe J.M., Lichtman M.A. Hyperleukocytosis and leukostasis: Common features of childhood chronic myelogenous leukemia. Blood 1984;63(5):1230–4.Hijiya N., Schultz K.R., Metzler M. et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 2016;127(4):392–9. DOI: 10.1182/blood­2015­06­648667Hijiya N., Millot F., Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin North Am 2015;62(1):107–19. DOI: 10.1016/j.pcl.2014.09.008Castagnetti F., Gugliotta G., Baccarani M. et al. GIMEMA CML Working Party. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol 2015;26(1):185–92. DOI: 10.1093/annonc/mdu490Millot F., Guilhot J., Suttorp M. et al. Advanced phases at diagnosis of childhood chronic myeloid leukemia: the experience of the international registry for chronic myeloid leukemia (CML) in children and adolescents (I­CML­Ped Study). Blood 2017;130:316.Ernst T., Busch M., Rinke J. et al. Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia 2018;32(9):2046–9. DOI: 10.1038/s41375­018­0157­2De la Fuente J., Baruchel A., Biondi A. et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 2014;167(1):33–47. DOI: 10.1111/bjh.12977Becerra­Pedraza L.C., Jiménez­Martínez L.E., Peña­Morfin I. et al. Priapism as the initial sign in hematologic disease: сase report and literature review. Int J Surg Case Rep 2018;43:13–7. DOI: 10.1016/j.ijscr.2017.12.038Kurosawa H., Tanizawa A., Tono C. et al. Leukostasis in children and adolescents with chronic myeloid leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016;63(3):406–11. DOI: 10.1002/pbc.25803Paladino N., Roldán D., Caram M.S. Priapismo en pediatría: presentación inicial de una leucemia mieloide crónica [Priapism in pediatrics: initial presentation of chronic myeloid leukemia (In Spanish)]. Arch Argent Pediatr 2011;109(5):e104–8. DOI: 10.1590/S0325­00752011000500016Fowler J.E.Jr, Koshy M., Strub M. et al. Priapism associated with the sickle cell hemoglobinopathies: prevalence, natural history and sequelae. J Urol 1991;145(1):65–8. DOI: 10.1016/s0022­ 5347(17)38248­4Chang M.W., Tang C.C., Chang S.S. Priapism – a rare presentation in chronic myeloid leukemia: case report and review of the literature. Chang Gung Med J 2003;26(4):288–92.Ponniah A., Brown C.T., Taylor P. Priapism secondary to leukemia: effective management with prompt leukapheresis. Int J Urol 2004;11(9):809–10. DOI: 10.1111/j.1442­2042.2004.00872.xBower H., Björkholm M., Dickman P.W. et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016;34(24):2851–7. DOI: 10.1200/JCO.2015.66.2866Suttorp M., Schulze P., Glauche I. et al. Front­line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia 2018;32(7):1657– 69. DOI: 10.1038/s41375­018­0179­9Millot F., Baruchel A., Guilhot J. et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011;29(20):2827–32. DOI: 10.1200/ JCO.2010.32.7114Champagne M.A., Fu C.H., Chang M. et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2011;57(1):56–62. DOI: 10.1002/pbc.23031Kodama Y., Sato A., Kato K. et al. Ponatinib in pediatric patients with Philadelphia chromosome­positive leukemia: a retrospective survey of the Japan Children’s Cancer Group. Int J Hematol 2022;116(1):131–8. DOI: 10.1007/s12185­022­03329­5Zwaan C.M., Rizzari C., Mechinaud F. et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180­018 phase I dose­escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 2013;31(19):2460–8. DOI: 10.1200/JCO.2012.46.8280Leung W.Y., Cheuk D.K., Cheng F.W. et al. Outcome prediction of chronic myeloid leukemia (CML) in children. Ann Hematol 2022;101(8):1677–88. DOI: 10.1007/s00277­022­04852­5Athale U., Hijiya N., Patterson B.C. et al. Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children’s Oncology Group CML Working Group. Pediatr Blood Cancer 2019;66(9):e27827. DOI: 10.1002/pbc.27827Hochhaus A., Saglio G., Hughes T.P. et al. Long­term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5­year update of the randomized ENESTnd trial. Leukemia 2016;30(5):1044–54. DOI: 10.1038/leu.2016.5Cortes J.E., Gambacorti­Passerini C., Deininger M.W. et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 2018;36(3):231–7. DOI: 10.1200/JCO.2017.74.7162Giles F.J., Mauro M.J., Hong F. et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non­tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27(6):1310–5. DOI: 10.1038/leu.2013.69Douxfils J., Haguet H., Mullier F. et al. Association between BCR­ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta­analysis. JAMA Oncol 2016;2(5):625–32. DOI: 10.1001/jamaoncol.2015.5932Dhar J., Chhabra G., Khandelwal L. et al. Priapism as a debut presentation of chronic myeloid leukemia. J Coll Physicians Surg Pak 2019;29(1):78–80. DOI: 10.29271/jcpsp.2019.01.78Montague D.K., Jarow J., Broderick G.A. et al. American Urolo­ gical Association guideline on the management of priapism. J Urol 2003;170(4 Pt 1):1318–24. DOI: 10.1097/01.ju.0000087608. 07371.ca